News

Filter

Current filters:

ruxolitinib

US FDA grants priority review as it accepts Incyte ruxolitinib NDA for myelofibrosis

04-08-2011

The US Food and Drug Administration has accepted for filing the New Drug Application (NDA) for drug developer…

IncyteNorth AmericaNovartisOncologyPharmaceuticalRegulationruxolitinib

Novartis blood cancer drug ruxolitinib meets Ph III endpoint

16-03-2011

Swiss drug major Novartis (NOVN: VX) revealed yesterday that it expects to file for approval in the second…

IncyteNovartisOncologyPharmaceuticalRare diseasesResearchruxolitinib

Back to top